Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Afya Limited

50.7% sales growth and 12.45% return on equity

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil.

Afya Limited’s sales growth this year is expected to be 67.3% and 35.6% for next year.

Year-on-year quarterly revenue growth grew by 49.7%, now sitting on N/A for the twelve trailing months.

Afya Limited’s sales growth for the next quarter is 50.7%. The company’s growth estimates for the present quarter and the next is 23.8% and 15.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.45%.

Afya Limited’s Stock Yearly Top and Bottom Value

Afya Limited’s stock is valued at $23.05 at 16:22 EST, way below its 52-week high of $30.98 and way above its 52-week low of $13.98.

Afya Limited’s Moving Average

Afya Limited’s worth is way under its 50-day moving average of $26.02 and below its 200-day moving average of $24.96.

2. JD.com

37% sales growth and 21.29% return on equity

JD.com, Inc., through its subsidiaries, operates as an e-commerce company and retail infrastructure service provider in the People’s Republic of China.

JD.com’s sales growth this year is anticipated to be 37% and 22.9% for next year.

Year-on-year quarterly revenue growth grew by 29.2%, now sitting on N/A for the twelve trailing months.

News about JD.com today

Chinese robocar maker plans hunt for fresh capital in new year. According to today’s article on Bloomberg Quint, “Investors include Baidu Inc. and JD.com Inc., according to Crunchbase.”

In China, online grocery shopping gets political. According to today’s article on The Wall Street Journal, ” JD.com agreed this month to invest $700 million in Xingsheng, a platform for community-group buying. ”

JD.com’s sales growth for the next quarter is 37%. The company’s growth estimates for the present quarter and the next is 200% and 82.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.29%.

JD.com’s Stock Yearly Top and Bottom Value

JD.com’s stock is valued at $85.29 at 16:22 EST, under its 52-week high of $92.77 and way above its 52-week low of $32.70.

JD.com’s Moving Average

JD.com’s value is higher than its 50-day moving average of $85.05 and way above its 200-day moving average of $74.04.

Previous days news about JD.com

Germany’s shuttered retailers turn to online rival for help. According to Bloomberg Quint on Sat Dec 19, “Keller said Zalando studied Chinese companies including Alibaba Group Holding Ltd., Tmall and JD.com Inc. for clues how to better link up offline inventories before introducing the service in 2016. ”

China’s online shopping addiction is killing its green packaging drive. According to Bloomberg Quint on Sun Dec 20, “and JD.com Inc. lure shoppers with huge bargains during the Singles’ Day bonanza. ”

China turns up pressure on its tech giants. According to The Wall Street Journal on Tue Dec 22, “Representatives from food-delivery app operator Meituan , e-commerce companies JD.com Inc. and Pinduoduo Inc. and ride-hailing platform Didi Chuxing Technology Co. also attended the meeting.”

3. The Bank of Princeton

21.6% sales growth and 6.57% return on equity

The Bank of Princeton provides various banking products and services.

The Bank of Princeton’s sales growth this year is expected to be 17.6% and 1.9% for next year.

Year-on-year quarterly revenue growth grew by 3.5%, now sitting on 46.43M for the twelve trailing months.

The Bank of Princeton’s sales growth for the next quarter is 21.6%. The company’s growth estimates for the present quarter and the next is 14.3% and 9.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.57%.

The Bank of Princeton’s Stock Yearly Top and Bottom Value

The Bank of Princeton’s stock is valued at $24.01 at 16:22 EST, way under its 52-week high of $32.25 and way above its 52-week low of $17.40.

The Bank of Princeton’s Moving Average

The Bank of Princeton’s value is higher than its 50-day moving average of $22.86 and way above its 200-day moving average of $20.28.

4. O2Micro International Limited

39.3% sales growth and 4.71% return on equity

O2Micro International Limited, together with its subsidiaries, designs, develops, and markets integrated circuits and solutions for power management components and systems in China, the United States, Taiwan, Japan, Malaysia, Korea, Singapore, and internationally.

O2Micro International Limited’s sales growth this year is anticipated to be 28.6% and 19.3% for next year.

Year-on-year quarterly revenue growth grew by 38.7%, now sitting on 72.96M for the twelve trailing months.

O2Micro International Limited’s sales growth for the next quarter is 39.3%. The company’s growth estimates for the present quarter and the next is 100% and 216.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.71%.

O2Micro International Limited’s Stock Yearly Top and Bottom Value

O2Micro International Limited’s stock is valued at $6.41 at 16:22 EST, way below its 52-week high of $8.35 and way above its 52-week low of $0.98.

O2Micro International Limited’s Moving Average

O2Micro International Limited’s value is below its 50-day moving average of $6.62 and way above its 200-day moving average of $3.70.

5. Regeneron Pharmaceuticals, Inc.

34.3% sales growth and 30.6% return on equity

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.

Regeneron Pharmaceuticals, Inc.’s sales growth this year is anticipated to be 8.5% and 20.2% for next year.

Year-on-year quarterly revenue growth grew by 31.6%, now sitting on 9.24B for the twelve trailing months.

Regeneron Pharmaceuticals, Inc.’s sales growth for the next quarter is 34.3%. The company’s growth estimates for the present quarter and the next is 13.3% and 27.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.6%.

Regeneron Pharmaceuticals, Inc.’s Stock Yearly Top and Bottom Value

Regeneron Pharmaceuticals, Inc.’s stock is valued at $479.77 at 16:22 EST, way below its 52-week high of $664.64 and way higher than its 52-week low of $328.13.

Regeneron Pharmaceuticals, Inc.’s Moving Average

Regeneron Pharmaceuticals, Inc.’s worth is way below its 50-day moving average of $534.72 and way below its 200-day moving average of $586.69.

6. Lincoln Educational Services Corporation

9.2% sales growth and 25.87% return on equity

Lincoln Educational Services Corporation, together with its subsidiaries, provides various career-oriented post-secondary education services to high school graduates and working adults in the United States.

Lincoln Educational Services Corporation’s sales growth this year is anticipated to be 6% and 9.5% for next year.

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 285.22M for the twelve trailing months.

Lincoln Educational Services Corporation’s sales growth for the next quarter is 9.2%. The company’s growth estimates for the present quarter and the next is a negative 33.3% and 225%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.87%.

Lincoln Educational Services Corporation’s Stock Yearly Top and Bottom Value

Lincoln Educational Services Corporation’s stock is valued at $7.95 at 16:22 EST, way under its 52-week high of $8.99 and way above its 52-week low of $1.69.

Lincoln Educational Services Corporation’s Moving Average

Lincoln Educational Services Corporation’s worth is way higher than its 50-day moving average of $6.20 and way above its 200-day moving average of $5.67.

7. D.R. Horton, Inc.

30.4% sales growth and 21.24% return on equity

D.R. Horton, Inc. operates as a homebuilding company in East, Midwest, Southeast, South Central, Southwest, and West regions in the United States.

D.R. Horton, Inc.’s sales growth this year is anticipated to be 22.9% and 11.9% for next year.

Year-on-year quarterly revenue growth grew by 27%, now sitting on 20.31B for the twelve trailing months.

D.R. Horton, Inc.’s sales growth for the next quarter is 30.4%. The company’s growth estimates for the ongoing quarter and the next is 44.8% and 41.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.24%.

D.R. Horton, Inc.’s Stock Yearly Top and Bottom Value

D.R. Horton, Inc.’s stock is valued at $73.23 at 16:22 EST, under its 52-week high of $81.21 and way higher than its 52-week low of $25.51.

D.R. Horton, Inc.’s Moving Average

D.R. Horton, Inc.’s value is above its 50-day moving average of $72.17 and above its 200-day moving average of $68.32.

8. Eli Lilly and Company

13.7% sales growth and 131.77% return on equity

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide.

Eli Lilly and Company’s sales growth this year is expected to be 8.8% and 11.6% for next year.

Year-on-year quarterly revenue growth grew by 4.8%, now sitting on 23.21B for the twelve trailing months.

Eli Lilly and Company’s sales growth for the next quarter is 13.7%. The company’s growth estimates for the present quarter and the next is 33.5% and 9.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 131.77%.

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $171.40 at 16:22 EST, under its 52-week high of $173.90 and way above its 52-week low of $117.06.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is way higher than its 50-day moving average of $148.65 and way above its 200-day moving average of $151.64.

Previous days news about Eli Lilly and Company

Data from actt-2 trial of baricitinib in hospitalized Covid-19 patients supportive of the u. s. FDA EUA published in new england journal of medicine. According to Business Insider on Sat Dec 19, “TORONTO, Dec. 19, 2020 /CNW/ -On December 11, 2020, Eli Lilly and Company and Incyte announced that The New England Journal of Medicine published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). “, “About Eli Lilly CanadaEli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. “

LEAVE A REPLY

Please enter your comment!
Please enter your name here